After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

The Zephyr Valve procedure is a minimally invasive treatment for severe or very severe COPD and emphysema. It offers an alternative to highly invasive options like lung transplants, which carry ...

It has been found in a recent study published in Heliyon that individuals who are genetically predisposed to having ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.